Kolltan Pharmaceuticals
Founded Year
2007Stage
Acquired | AcquiredTotal Raised
$135MValuation
$0000About Kolltan Pharmaceuticals
Kolltan Pharmaceuticals is a clinical-stage company focused on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases (RTKs). Focused primarily in oncology and backed by prominent thought leaders in RTK biology, Kolltan has reported clinical and preclinical data that its drug candidates can help overcome tumor resistance mechanisms associated with current tyrosine kinase inhibitors and seen in patients who have failed other cancer therapies.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Kolltan Pharmaceuticals Patents
Kolltan Pharmaceuticals has filed 8 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/10/2015 | 8/18/2020 | Tyrosine kinase receptors, Experimental cancer drugs, Monoclonal antibodies, Clusters of differentiation, Transcription factors | Grant |
Application Date | 4/10/2015 |
|---|---|
Grant Date | 8/18/2020 |
Title | |
Related Topics | Tyrosine kinase receptors, Experimental cancer drugs, Monoclonal antibodies, Clusters of differentiation, Transcription factors |
Status | Grant |
Latest Kolltan Pharmaceuticals News
Oct 7, 2018
Printed From BioPortfolio.com Kolltan Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 28072018] Prices from USD $350 20:46 EDT 6 Oct 2018 | BioPortfolio Reports Kolltan Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Summary Marketline's Kolltan Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Kolltan Pharmaceuticals, Inc. since January2007. Synopsis Marketline's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights This report includes Kolltan Pharmaceuticals, Inc.'s contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed. The profile also includes detailed deal reports for all MA, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Kolltan Pharmaceuticals, Inc.. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed. Scope Provides intelligence on Kolltan Pharmaceuticals, Inc.'s MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Kolltan Pharmaceuticals, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Kolltan Pharmaceuticals, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. Reasons to buy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Kolltan Pharmaceuticals, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News
Kolltan Pharmaceuticals Frequently Asked Questions (FAQ)
When was Kolltan Pharmaceuticals founded?
Kolltan Pharmaceuticals was founded in 2007.
Where is Kolltan Pharmaceuticals's headquarters?
Kolltan Pharmaceuticals's headquarters is located at 300 George Street, New Haven.
What is Kolltan Pharmaceuticals's latest funding round?
Kolltan Pharmaceuticals's latest funding round is Acquired.
How much did Kolltan Pharmaceuticals raise?
Kolltan Pharmaceuticals raised a total of $135M.
Who are the investors of Kolltan Pharmaceuticals?
Investors of Kolltan Pharmaceuticals include Celldex Therapeutics, HBM Healthcare Investments, Purdue Pharma, Deerfield Management, Osage University Partners and 9 more.
Who are Kolltan Pharmaceuticals's competitors?
Competitors of Kolltan Pharmaceuticals include Constellation Pharmaceuticals, Ology Bioservices, Cellworks, Adastra Pharmaceuticals, Vaccinex and 15 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Kolltan Pharmaceuticals to Competitors
Kanisa Pharmaceuticals is a pharmaceutical company focused on the acquisition, development and commercialization of therapeutics in the field of oncology.
VGXI is a contract manufacturer of plasmid DNA. The company delivers flexibility, experience, reliability, and value to clients’ challenging programs. The company’s cGMP and non-cGMP products have passed rigorous international regulatory reviews.
Adastra Pharmaceuticals is a private, clinical-stage biopharmaceutical company committed to providing responsible solutions to advance patient care in oncology. Its vision is to identify, develop, and deliver to patients important new therapies for diseases with significant unmet needs. This commitment is epitomized by its lead clinical candidate, zotiraciclib, which is initially being developed for the treatment of high-grade gliomas (HGG) and diffuse intrinsic pontine glioma (DIPG), two forms of brain cancer characterized by Myc overexpression. Adastra possesses a rich history of institutional and academic collaboration, including ongoing clinical research programs with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC).
Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.
KeyNeurotek Pharmaceuticals is a clinical stage small molecule company focused on autoimmune and CNS diseases.
Founded in early 2002 by Avalon Ventures and Domain Associates, Ansata Therapeutics is developing & commercializing novel medicines that capitalize on the Company's industry- leading expertise and intellectual property in molecular transduction. Ansata has several preclinical programs under development in the oncology and neurodegenerative disease areas. The company strives to rapidly advance lead compounds from late-stage preclinical research into clinical development by leveraging its proprietary knowledge of common dermatological diseases.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
